AUPH

Aurinia Pharmaceuticals
AUPH

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.11B
EV
$870.48M
Shares Outstanding
135.10M
Beta
1.16

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$10.00
P/E 2025E
13.96x
P/Revenue 2025E
4.27x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Aurinia Pharmaceuticals Inc.

gainify
AUPH

Aurinia Pharmaceuticals Inc.

AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active l...

Sector

Healthcare

Industry

Biotechnology

CEO

Greenleaf, Peter

Employees

130

IPO Date

2014-09-03

Headquarters

118 Avenue 14315, Suite 140, Edmonton, Alberta, T5L 4S6, Canada

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.